State of the art laboratories

Research in to the basic, epidemiological, preventive, clinical and translational aspects of leukemia and other hematologic malignancies

A New Partnership of Public, Private and Competitive Funding

Patients, Scientists, Doctors; working together to cure leukemia

Research centred on patients

Caring research


Recent publications

Sorigué M, Xicoy B, Grifols JR, Ribera JM

[Autoimmune hemolytic anemia refractory to medical treatment after chlorine dioxide intake in a patient with idiopathic thrombocytopenic purpura].

Med Clin (Barc) 8 Apr 2015, 144 (7) 332-3. Epub 18 Jun 2014More information
Oliveira AC, Fernández de Sevilla A, Domingo A, De La Banda E, Domingo-Domènech E, Mercadal S, Ruiz-Xivillé N, Alonso E, Encuentra M, González-Barca E

Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 × 10(9)/L monoclonal lymphocytes better identifies subgroups with different outcomes.

Ann. Hematol. Apr 2015, 94 (4) 627-32. Epub 5 Dec 2014
The arbitrary threshold of 5 × 10(9)/L chronic lymphocytic leukemia (CLL)-like lymphocytes differentiates monoclonal B lymphocytosis (MBL) from CLL. There are no prospective studies that search for the optimal cut-off of monoclonal lymphocytes able to predict outcome and simultaneously analyze the prognostic value of classic, immunophenotypic, and cytogenetic variables in patients with asymptomatic clonal CLL lymphocytosis (ACL), which includes MBL plus Rai 0 CLL patients. From 2003 to 2010, 231 ACL patients were enrolled in this study. Patients with 11q deletion and atypical lymphocyte morphology at diagnosis had shorter progression-free survival (PFS) (p = 0.007 and p = 0.015, respectively) and treatment-free survival (TFS) (p = 0.009 and p = 0.017, respectively). Elevated beta-2 microglobulin (B2M) also correlated with worse TFS (p = 0.002). The optimal threshold of monoclonal lymphocytes independently correlated with survival was 11 × 10(9)/L (p = 0.000 for PFS and p = 0.016 for TFS). As conclusion, monoclonal lymphocytosis higher than 11 × 10(9)/L better identifies two subgroups of patients with different outcomes than the standard cut-off value of 5 × 10(9)/L. Atypical lymphocyte morphology, 11q deletion and elevated B2M had a negative impact on the survival in ACL patients.
More information
Arora M, Hemmer MT, Ahn KW, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RP, Inamoto Y, Weisdorf DJ, Li P, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman SR, Pavletic SZ, Lee SJ, Horowitz MM, Flowers ME

Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort.

Biol. Blood Marrow Transplant. Apr 2015, 21 (4) 640-5. Epub 18 Dec 2014
We previously reported a risk score that predicted mortality in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (HCT) between 1995 and 2004 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to validate this risk score in an independent CIBMTR cohort of 1128 patients with CGVHD who underwent transplantation between 2005 and 2007 using the same inclusion criteria and risk score calculations. According to the sum of the overall risk score (range, 1 to 12), patients were assigned to 4 risk groups (RGs): RG1 (0 to 2), RG2 (3 to 6), RG3 (7 to 8), and RG4 (9 to 10). RG3 and RG4 were combined, as RG4 accounted for only 1% of the total cohort. Cumulative incidences of nonrelapse mortality (NRM) and probability of overall survival were significantly different between each RG (all P < .01). NRM and overall survival at 5 years after CGVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectively (all P < .01). Our study validates the prognostic value of the CIBMTR CGVHD RGs for overall survival and NRM in a contemporary transplantation population. The CIBMTR CGVHD RGs can be used to predict major outcomes, tailor treatment planning, and enroll patients in clinical trials.
More information
Castillo N, García-Cadenas I, García O, Barba P, Diaz-Heredia C, Martino R, Azqueta C, Ferrà C, Canals C, Elorza I, Olivé T, Badell I, Sierra J, Duarte R, Valcárcel D, Querol S

Few and Nonsevere Adverse Infusion Events Using an Automated Method for Diluting and Washing before Unrelated Single Cord Blood Transplantation.

Biol. Blood Marrow Transplant. Apr 2015, 21 (4) 682-7. Epub 27 Dec 2014
Graft dilution and DMSO washing before cord blood (CB) administration using an automated system may offer low incidence of adverse infusion events (AIE), ensuring reproducible cell yields. Hence, we analyzed the incidences and significance of immediate AIE, cellular yield, and engraftment after single CB infusion. One hundred and fifty-seven patients (median age, 20 years; range, 1 to 60) received a single CB unit for treatment of hematologic and nonhematologic malignancies with myeloablative conditioning after graft dilution and washing. The median total nucleated cell (TNC) doses was 3.4 × 10(7)/kg (range, 2 to 26) and the median post-thaw recovery was 84% (range, 45 to 178). The cumulative incidence of neutrophil engraftment at 50 days was 84% (95% confidence interval [CI], 83 to 93). A total of 118 immediate AIE were observed in fifty-two (33%) patients. All reported AIE were transient, graded from 1 to 2 by Common Terminology Adverse Events version 4. The most frequent toxicity was cardiovascular but without any life-threatening reaction. Infused TNC, recipient's weight, and rate of infusion per kilogram were risk factors associated with cardiovascular AIE in multivariate analysis (odds ratio [OR], 1.2 (95% CI, 1.1 to 1.4); P < .001; OR, .94 (95% CI, .9 to .97); P < .001; and OR, 1.5 (95% CI, 1.2 to 1.8); P < .001; respectively). In summary, use of an automated method for graft washing before CB administration showed low incidence of AIE without compromising cell yields and engraftment. Infused TNC dose, recipient's weight, and rate of infusion per kilogram were risk factors associated with infusion reactions.
More information
Zamora L, Xicoy B, Cabezón M, Fernandez C, Marcé S, Velez P, Xandri M, Gallardo D, Millá F, Feliu E, Boqué C

Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.

Leuk. Lymphoma 11 Mar 2015, 1-2. Epub 11 Mar 2015More information